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Abstract: Some novel Schiff bases derived from 1-(2-ketoiminoethyl)piperazines were 
synthesized and characterized by mass spectroscopy, FTIR, UV-Visible, 1H and 13C-NMR. 
The compounds were tested for inhibitory activities on human acetylcholinesterase 
(hAChE), antioxidant activities, acute oral toxicity and further studied by molecular 
modeling techniques. The study identified the compound (DHP) to have the highest 
activity among the series in hAChE inhibition and DPPH assay while the compound LP 
revealed the highest activity in the FRAP assay. The hAChE inhibitory activity of DHP is 
comparable with that of propidium, a known AChE inhibitor. This high activity of DHP 
was checked by molecular modeling which showed that DHP could not be considered as a 
bivalent ligand due to its incapability to occupy the esteratic site (ES) region of the 3D 
crystal structure of hAChE. The antioxidant study unveiled varying results in 1,1-diphenyl-
1-picrylhydrazyl (DPPH) and ferric reducing antioxidant power (FRAP) assays. This 
indicates mechanistic variations of the compounds in the two assays. The potential 
therapeutic applications and safety of these compounds were suggested for use as human 
acetylcholinesterase inhibitors and antioxidants. 
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1. Introduction 
The neurodegenerative disorder characterized by the nerve cell dysfunctions and loss of neurons in 
the central nervous system was first discovered in 1907 by a German scientist, Alois Alzheimer, and 
was named as Alzheimer’s disease (AD). Millions of people are reported to fall victims of this 
traumatic problem worldwide [1]. At the early stages, the patient is faced with a decline in cognitive 
functions, exclusively short-term memory, which later resulta in the incapability to read, speak and/or 
think rationally [2]. Recent reports on curative approaches to this ailing disease are based on the 
assumption of a cholinergic mechanism, with particular emphasis on acetylcholinesterase inhibition [2,3]. 
Indeed, many scientific trials have been conducted in order to discover typical and non-toxic drug for 
the treatment of AD. The most commonly used drug for the treatment of AD is tacrine which is 
recognized to have so many side effects that in most cases they lead to withdrawal of the medication. 
Other drugs like donepezil, rivastigmine, galanthamine, caproctamine and memantine were also used 
for the treatment of AD, but are known for their unfavorable effects like hepatotoxicity, 
gastrointestinal disturbance, dizziness, diarrhea, vomiting and nausea [4-6]. The key factor liley 
implicated in many diseases is oxidative stress caused by free radicals produced as a result of an 
imbalance in antioxidants produced by the cells [7]. This suggests that treatment of AD should involve 
acetylcholinesterase inhibitors and antioxidants that can scavenge the excess free radicals and 
antagonize the consequences of oxidative stress [8,9]. In addition, the literature reports that many 
standard drugs contain a polyamine backbone in their structures (Figure 1), and that the AChE gorge is 
lined with various preserved aromatic residues which in principle can form cation-π bonds with a basic 
polyamine counterpart [10,11]. This study therefore sought to synthesize and characterize some new 
compounds capable of AChE binding site inhibition and compares their activity with that of standard 
drugs like tacrin and propidium. These compounds have flexidentate behavior and contain secondary 
and tertiary amines in their structures akin to the secondary amino function found in tacrine dimer [12] 
and the tertiary amino group of donepezil [13]. Moreover, the compounds were tested for acute 
toxicity and antioxidant activities using the FRAP and DPPH assays due to arising demands for 
compounds that are safe and possess dual AChE inhibition and antioxidant activities [14,15]. 
Figure 1. Acetylcholinesterase inhibitors. 
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2. Results and Discussion 
2.1. Chemistry 
The reaction of 2-(piperazin-1-yl)ethanamine with selected ketones resulted in the formation of the 
corresponding 1-(2-ketoiminoethyl)piperazines that exhibited NMR, IR and UV-Visible spectra 
consistent with the proposed structures that allowed the synthesized compounds to be identified as  
2-(piperazin-1-yl)-N-(1-(pyridin-2-yl)ethylidene)ethanamine (LP), 2-(1-(2-piperazin-1-yl)ethylimino) 
ethyl)phenol (2HP) and 4-(1-(2-piperazin-1-yl)ethylimino)ethyl)benzene-1,3-diol (DHP), respectively 
(Scheme 1). 
Scheme 1. Reaction pathway. 
O
OH
O
OHHO
N
N
N
N
OH
OHHO
N
NH
N
NH
N
NH
EtOH,Reflux, 75-85oC, Concentrate
EtOH,Ref lux, 75-85
o
C, Concentrate
N
O
N
NH
H2N
EtOH,Reflux, 75-85oC, Concentrate
1-(pyridin-2-yl)ethanone
2-(piperazin-1-yl)ethanamine (E)-2-(piperazin-1-yl)-N -(1-(pyridin-2-
yl)ethylidene)ethanamine
1-(2-hydroxyphenyl)ethanone
(E)-2-(1-(2-(piperazin-1-
yl)ethylimino)ethyl)phenol
N
NH
H2N
2-(piperazin-1-yl)ethanamine
1-(2,4-dihydroxyphenyl)ethanone
N
NH
H2N
2-(piperazin-1-yl)ethanamine
(E)-4-(1-(2-(piperazin-1-
yl)ethylimino)ethyl)benzene-1,3-diol  
The IR spectra of all the compounds revealed complete absence of the characteristic ketonic 
carbonyl and displayed absorptions at wavelengths of 1,654, 1,616, and 1,595 cm−1 for LP, 2HP and 
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DHP, respectively, which correspond to the characteristic iminic frequency [16,17], thus, confirming 
the formation of Schiff bases. The broad bands observed at 3,394 cm−1 in the spectra of 2HP and DHP 
could be attributed to the phenolic intra-molecular hydrogen bonding of their O–H groups [18]. Other 
series of bands observed in the spectra of compounds LP, 2HP and DHP in the wavelength ranges 
{2,823, 2,821, 2,833 cm−1}, {1,459, 1,302, 1,243 cm−1} {1,152, 1,152, 1,137cm−1} can be assigned to 
υ(C-H) aliphatic, υ(C-C) aromatic and υ(C-N) stretching vibrations, respectively [19,20]. 
The proton NMR spectra of the Schiff bases revealed a singlet δ 1.13–2.01 which is due to a methyl 
group shielded by the imine moiety. The compound LP did not show the presence of OH protons 
which are observed in the spectra of 2HP and DHP at δ 6.74 ppm and δ 6.17 ppm, respectively, and 
instead it shows triplet at δ.7.43–7.84. In the 13C-NMR spectra of the compounds LP, 2HP and DHP 
the methylene group peak overlaps with DMSO solvent peak at δ 39–46, while the aromatic carbons 
were observed at around δ 120 in all the spectra. In addition the compounds gave M+H ion peaks in 
the mass spectra. The liquid chromatography electron spray ionization mass spectrum (LC-ESI-MS) of 
compound LP gave a molecular ion peak of 232.07 Da which correlates to the calculated weight of 
C13H20N4 (232.17), thus proving the purity of the compound. The compound 2HP also shows a 
molecular ion peak at 247.11 Da, also very close to the calculated weight of C14H21N3O (247.17). 
Finally, the mass spectrum of DHP gave a [M+H] molecular ion peak of 264.17 Da whereby the 
calculated mass for C14H21N3O2 is 263.16. This is in complete agreement with the proposed structure 
and also proves the purity of the compound (Figure 2). IR and UV-Visible spectral data were also all 
in accordance with the assigned structures The UV-visible spectra of the compounds LP, 2HP and 
DHP shows absorption bands at 284, 242 and 215 nm respectively, which may be assigned to benzene 
ring π→π* transitions [21-25]. 
Figure 2. Mass spectra for the compounds LP, 2HP and DHP. 
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Figure 2. Cont. 
 
2.2. Anti-AChE Assay 
The inhibitory activities of the compounds LP, 2HP and DHP on human acetylcholinesterase were 
9.9, −4.0, and 21.8% respectively (Table 1). The activities were only fair when compared to the 
standard drugs tacrin and propidium used in this study which showed inhibitions of 76.6% and 28.2%, 
respectively. The results indicated that the compound DHP had the highest activity which can be 
ascribed to the increased resonance effect caused by the hydroxyl group of the aromatic ring. 
Table 1. Human AChE inhibitory effects and anti-oxidant activities of LP, 2HP and DHP. 
Compounds  
Molecular 
Weight 
AChE Inhibition 
(Final concentration = 1 × 10−4 M) 
DPPH 
(IC50, µg/mL) 
FRAP value 
(Mean ± SD) 
LP 232.3 9.9 ± 3.1 - 1464.7 ± 5.2 
2HP 247.3 −4.0 - 293.3 ± 6.2 
DHP 263.3 21.8 ± 1.2 25 ± 1.24 355.3 ± 5.8 
Propidium - 28.2 ± 2.4 - - 
Tacrine - 76.6 ± 5.1 - - 
Ascorbic acid - - 1.4 ± 0.71 1552.7 ± 4.2 
BHT - - NA 187.3 ± 2.6 
LP: Schiff base derived from 2-acetylpyridine, 2HP: Schiff base derived from 2-hydroxy-acetophenone; 
DHP: Schiff base derived from dihydroxyacetophenone; BHT: Butylated hydroxytoluene (standard positive 
antioxidant); NA: not applicable. 
2.3. Molecular Docking 
The crystal structure of hAChE (pdb id: 1B41) shows that this enzyme possesses a deep narrow 
gorge which penetrates halfway into the enzyme, where the catalytic site resides [26]. Conversely, 
hAChE shares a certain degree of similarity with both mAChE and TcAChE, especially the active-site 
gorge due to their high degree of sequence identities of 87% and 53%, respectively. Generally, the 
catalytic site of AChE consists of five regions, which are the peripheral anionic site (PAS), the acyl 
pocket, the esteratic site (ES), the oxyanion hole (OH) and the anion subsite (AS). A similar catalytic 
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site is also observed in hAChE, PAS (Tyr 72, Tyr 124, Tyr 341, Asp 74 and Trp 286 residues), the acyl 
pocket (Phe 297, Phe 295 and Phe 338 residues), CT (Ser 203, His 447 and Glu 202 residues), OH 
(Gly 121, Gly 122 and Ala 204 residues) and AS (Trp 86 and Glu 202 residues). A molecular docking 
simulation (Figure 3) showed that DHP is well positioned at the active-site gorge. The hydrophobic 
interaction between DHP (the piperazine and the alkyl linker) and the rich aromatic contents (Tyr 124, 
Tyr 341, Tyr 337, Phe 338, Phe 297 and Trp 286) along the gorge could potentially direct the phenyl 
ring to penetrate deep into the anionic site and oxyanion hole regions in the choline-binding site. This 
interaction is further intensified, where three hydrogen bonding were found between DHP and the 
residues in the active site. This includes hydrogen bonding between the tertiary nitrogen of the 
piperazine ring with Tyr 124 residue at a distance of 2.42 Å. Two hydrogen bonding interactions 
between the imine group and two amino residues along the gorge which are Tyr 124 (3.05 Å) and Tyr 
337 (2.91 Å) were also observed during the docking experiment (Figures 3A and 3C). 
Figure 3. A close view of the potential interaction between DHP and the binding site of 
hAChE (pdb id: 1B41). A: Binding interactions of DHP in the catalytic site of TcAChE 
(green stick = compound 5). The most important residues involved in the interactions with 
DHP including the peripheral anionic site (PAS) and anionic subsite (choline-binding 
subsite); B: The 2D representation docking result of DHP with the residues in the active 
site of hAChE; C: Interatomic contacts (yellow) of the ligand with the residues in the 
active site of hAChE. 
 
These interactions could possibly help to dock the phenyl moiety to the anionic site. We believe that 
apart from the hydrophobic interactions, these hydrogen bonding effects are crucial for the AChE 
inhibition activity shown by DHP. It was clearly observed that DHP exhibited much higher AChE 
inhibition activity in comparison with LP and 2HP. It becomes visibly clear that the para-hydroxyl 
group functionality plays an important role in the inhibition activity. Close inspection of the docking 
results revealed that the para-hydroxyl group is in close proximity (within the range of 3.13 Å) to the 
hydroxyl of the Tyr 124 side chain. This interaction could possibly aid the phenyl ring of DHP to 
engage in a π-π stacking interaction with the indole ring of Trp 86 (Figure 3B). It is known that 
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inhibitors such as acridine exhibit such interactions with the conserved residue of Trp 86 [27]. Overall, 
the binding of DHP is energetically favorable, with a predicted –CDOCKER energy of 19.148 and  
–CDOCKER interaction energy of 40.816. 
2.4. Antioxidant Assays 
The antioxidant efficacies of the Schiff bases LP, 2HP, and DHP were tested and the results 
obtained revealed different activities in the two assays. This indicates that two mechanisms operating 
in different ways must be responsible for the observed activity. The color change from deep purple to 
yellow at 515 nm observed in the DPPH assay has confirmed the radical scavenging activity of the 
compounds. A reference curve of absorbance (A) against DPPH concentration in methanol was plotted 
and used for the calculation of DPPH concentration at various reaction times (R2 = 0.9999). Only the 
compound DHP shows IC50 values of 25 µg/mL among the series (Table 1). The positive control used 
(ascorbic acid) showed an IC50 value of 1.4 ± 0.71 µg/mL. The high activity of the compound DHP in 
the DPPH assay can be related to the resonance effect of the hydroxyl at the meta-position to the 
phenolic group in the compound, whereupon electron donating substituents increase the electron 
density into the aromatic ring making it more reactive towards electrophilic attack. This presumably 
promotes the release of phenolic hydrogen to the (1,1-diphenyl-2-picrylhydrazyl) free radical indicated 
by a color change from purple to yellow. 
The second method used for testing the antioxidant activities of these compounds was the FRAP 
assay. It is considered an accurate method for assessing “antioxidant power”. Ferric to ferrous ion 
reduction at low pH causes a colored ferrous-tripyridyltriazine complex to form. FRAP values are 
obtained by comparing the absorbance change at 593 nm in test reaction mixtures with those 
containing ferrous ions at known concentrations. In this study, the compounds LP, 2HP and DHP 
showed FRAP assay values of 1,464.7, 293.3, and 355.3, respectively (Table 1) which is above the 
value of 187.3 shown by BHT, but below the value of 1,552.7 observed for ascorbic acid used as 
standards. It was observed that DHP demonstrates the highest potential activities in the DPPH assay 
while LP shows the highest in FRAP assay. The high activity of LP can seemingly be due to increased 
in π-electron delocalization within the pyridine ring which increases the electron density and causes 
ferric ion to change to ferrous [28]. 
2.5. Acute Toxicity 
Oral administration of 1-(2-ketoiminoethyl)piperazines at doses lower than 5 g/kg causes no 
apparent toxicity. However, above 5 g/kg the 1-(2-ketoiminoethyl)piperazines slowed animal 
movement, decreased aggressiveness, and touch and pain sensibility were noticed. The animals did not 
show gross negative behavioral changes such as excitement, respiratory distress, convulsions or coma. 
All the observed signs appeared 2–3 h after 1-(2-ketoiminoethyl)piperazine administration and 
disappeared dose-dependently. No mortality was observed up to 14 days. The biochemical data 
showed no significant change in serum albumin, liver enzymes (AST, ALT and ALP), total protein 
content, globulins, conjugated and total bilurubin. Blood concentrations of creatinine, urea, sodium, 
potassium, chloride carbon dioxide and anion gap were analyzed. All the parameters checked were 
found within the expected range in the animals treated with the compounds (P < 0.05–0.001) when 
compared to the normal (control) group (Tables 2 and 3). 
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Table 2. Renal function test of rats used in acute toxicity assessments of 1-(2-ketoiminoethyl)piperazine Schiff bases. 
Animals Sodium (mmol/L) 
Potassium 
(mmol/L) 
Chloride 
(mmol/L) 
Carbon 
dioxide 
(mmol/L) 
Anion gap 
(mmol/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Control 132.9 ± 2.1 6.14 ± 2.5 111.30 ± 3.5 16.12 ± 2.6 32.80 ± 2.9 7.40 ± 2.5 29.45 ± 9.6 
2HP (2 g/kg) 132.2 ± 3.5 6.27 ± 4.1 108.24 ± 4.2 19.18 ± 0.8 29.60 ± 1.2 7.10 ± 4.2 27.60 ± 6.4 
2HP (5 g/kg) 133.1 ± 4.1 6.35 ± 3.2 106.31 ± 3.8 17.51 ± 2.7 29.50 ± 3.6 7.30 ± 3.7 25.91 ± 8.3 
DHP (2 g/kg) 133.5 ± 0.9 6.29 ± 0.4 109.71 ± 6.2 18.31 ± 0.4 28.70 ± 4.2 6.90 ± 2.1 26.22 ± 2.1 
DHP (5 g/kg) 134.1 ± 1.8 6.37 ± 0.7 108.19 ± 2.4 19.72 ± 0.8 30.40 ± 3.2 7.10 ± 1.4 28.47 ± 1.6 
LP (2 g/kg) 131.3 ± 2.2 6.52 ± 0.9 110.32 ± 2.1 18.34 ± 1.3 31.20 ± 2.5 7.01 ± 0.9 27.90 ± 1.3 
LP (5 g/kg) 133.1 ± 0.4 6.44 ± 1.2 107.82 ± 3.2 14.26 ± 1.5 33.10 ± 3.4 6.8 0± 2.1 30.13 ± 0.4 
Values expressed as mean ± S.E.M. There are no significant differences between groups. Significant value at p < 0.05. 
Table 3. Liver function test of rats used in acute toxicity assessments of 1-(2-ketoiminoethyl)piperazine Schiff bases. 
Animals Total protein (g/L) 
Albumin 
(g/L) 
Globulin 
(g/L) 
TB 
(µmol/L) 
CB 
(µmol/L) 
AP 
(IU/L) 
ALT 
(IU/L) 
AST 
(IU/L) 
Control 64.10 ± 2.2 18.40 ± 1.1 50.90 ± 2.3 6.20 ± 0.2 3.20 ± 0.6 104.20 ± 12.4 56.20 ± 4.9 220.12 ± 4.9 
2HP (2 g/kg) 65.00 ± 2.7 18.20 ± 1.2 51.60 ± 2.1 8.30 ± 0.3 4.30 ± 0.2 110.10 ± 11.3 62.12 ± 4.4 236.23 ± 6.1 
2HP (5 g/kg) 66.12 ± 2.2 19.20 ± 1.1 49.90 ± 2.5 9.50 ± 0.6 5.20 ± 0.4 101.50 ± 10.8 6515 ± 4.6 232.18 ± 4.3 
DHP (2 g/kg) 64.21 ± 2.6 20.10 ± 1.2 52.10 ± 2.5 8.90 ± 0.6 6.40 ± 0.5 106.40 ± 11.2 71.15 ± 3.8 235.21 ± 4.7 
DHP (5 g/kg) 66.16 ± 2.1 20.30 ± 1.3 54.20 ± 2.6 9.10 ± 0.8 6.60 ± 0.4 115.30 ± 10.8 70.67 ± 4.3 242.16 ± 5.1 
LP (2 g/kg) 65.32 ± 2.4 21.20 ± 1.8 50.10 ± 2.5 7.90 ± 0.9 7.10 ± 0.8 118.20 ± 10.5 69.45 ± 4.4 239.31 ± 4.8 
LP (5 g/kg) 63.23 ± 2.3 18.40 ± 1.6 52.20 ± 2.6 8.80 ± 0.4 7.20 ± 0.8 114.50 ± 10.1 68.35 ± 4.1 234.17 ± 4.6 
Values expressed as Mean ± S.E.M. There are no significant differences between groups. Significant value at p < 0.05 TB: Total bilirubin; CB: Conjugated 
bilirubin; AP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.  
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3. Experimental 
3.1. General 
The compounds synthesized in this study were characterized by spectral methods. Mass spectra 
were determined using a ABI 4800 Maldi TOF/TOF mass spectrophotometer (BIDMC Genomics, 
Proteomics And Bioinformatics Core, Boston, MA, USA) (LC-MS, ESI, 125.0 V), IR spectra was 
recorded at the wavelength range from 4,000–400 cm−1 using a Perkin Elmer 783 spectrophotometer, 
NMR spectra were obtained on a ECA400 FT-NMR spectrophotometer using TMS as internal 
standard, UV-visible spectra were recorded on a UV-1650PC model UV-visible spectrophotometer. 
3.2. 2-(Piperazin-1-yl)-N-(1-(pyridin-2-yl) ethylidene)ethanamine (LP) 
A stoichiometric amount of 2-(piperazin-1-yl)ethanamine (0.13 g, 1 mmol) in an absolute  
ethanol (25 mL) was refluxed with 1-(pyridine-2-yl)ethanone (0.12 g, 1 mmol) also dissolved in 
ethanol (25 mL) at a temperature of 75–85 °C for 3 h, to give an orange solution which after 
evaporation gave a brownish-red oil. The oily product produced a hygroscopic solid after three days. 
This was dissolved in methanol and heated to 55–60 °C with addition of a few drops of NaClO4 (0.1 g) 
taken in methanol (1 mL). The product, after evaporating the solvent under reduced pressure, formed a 
brown solid. Recrystallization from a 70:30 methanol/water mixture was performed to give 0.098 g of 
the title compound (42.2% yield). IR (KBr, cm−1) 3,413 s υ (N-H), 2,838 s υ (C-H), 1,633 s υ (C=N), 
1,271 s υ (C-C), 1,134 s, υ (C-N).1H-NMR (DMSO-d6), δ, ppm: 1.77 (s, 3H, CH3-iminic), 2.24 (s, 1H, 
NH), 2.43 (d, 4H, 2CH2N), 2.63 (t, 4H, 2CH2NH), 7.43 (t, 1H, arH, CHCHN), 7.84 (t, 1H, arH, 
CHCHCHN), 8.04 (d, 1H, arH, CHCHCHCHN), 8.60 (d, 1H, pyridinic). 13C-NMR (DMSO-d6), δ, 
ppm: 14.12 (CH3), 29.24 (CH2), 39.99–46.10 (DMSO-d6 + CH2), 49.12 (CH2), arC: [121.65 (CH), 
124.91 (CH), 136.97 (CH), 149.72 (CH), 166.8 (CH)]; UV: 284 nm (3075.25 mol−1Lcm−1),  
351 nm (3313.43 mol−1Lcm−1). MS: calc. m/z 232.17, found 232.07. 
3.3. 2-(1-(2-Piperazin-1-yl)ethylimino)ethyl)phenol (2HP) 
An ethanolic solution (25 mL) containing 2-(piperazin-1-yl)ethanamine (0.13 g, 1 mmol) was 
refluxed with 1-(2-hydroxyphenyl)ethanone (0.14 g, 1 mmol) in ethanol (25 mL) for 3 h at a 
temperature of 75–85 °C. A golden yellow solution was formed which after evaporating the solvent 
produced a yellow oil. This produces a hygroscopic solid after five days under vacuum. The solid 
product was dissolved in methanol at 55–60 °C. Solid NaClO4 (0.1 g) was added to the solution while 
it was hot and the suspension was immediately filtered. The filtrate was concentrated in air to give a 
needle-like microcrystalline solid after three days. The yellowish crystals were collected by filtration, 
washed with diethyl ether and recrystallized from a hexane-dichloromethane mixture (70:30), but the 
quality of the crystals was not suitable for x-ray diffraction. Yield: 0.124 g (50.2%). IR (KBr, cm−1) 
3,394 s υ (N-H), 2,821 s υ (C-H), 1,616 s υ (C=N), 1,302 s υ (C-C), 1,152 s υ (C-N). 1H-NMR 
(DMSO-d6), δ, ppm: 1.13 (s, 3H, CH3-iminic), 2.38 (s, 1H, NH), 2.57 (d, 4H, 2CH2N), 2.60 (t, 4H, 
2CH2NH), 6.78 (m, arH, CHCHCHCHCOH), 7.26 (m, arH, CHCHCOH), 7.28 (m, 1H, arH, 
CHCHCHCOH), 7.59 (m, arH, CHCHCOH), 7.61 (d, 1H, phenolic) 13C-NMR (DMSO-d6), δ, ppm: 
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19.03 (CH3), 28.15 (CH2), 39.73–46.52 (DMSO-d6 + CH2), 54.80–59.08 (CH2), arC: [116.78 (CH), 
118.88 (CH), 131.79 (CH), 132.84 (CH), 164.88 (CH), 172.92 (CH)]; UV: 262 nm (30490.97 mol−1Lcm−1), 
318 nm (14590.03 mol−1Lcm−1). MS: calc. m/z 247.17, found 244.97 (M + H). 
3.4. 4-(1-(2-Piperazin-1-yl)ethylimino)ethyl)benzene-1,3-diol (DHP) 
A weighed amount of 2-(piperazin-1-yl)ethanamine (0.13 g, 1 mmol) in ethanol (25 mL) was mixed 
with a stirred ethanolic solution (25 mL) of 1-(2,4-dihydroxyphenyl)ethanone (0.15 g, 1 mmol) at 
room temperature and refluxed for 3 h to give a clear orange solution. This was evaporated a using 
rotary evaporator to obtain an orange oil which after one week produces a white hygroscopic solid. 
The solid product was dissolved in methanol and heated to 55–60 °C. Solid NaClO4 (0.1 g) was added 
to the solution while hot and the suspension was filtered instantly. The filtrate produces a white solid 
after cooling. which was filtered off, washed with an ethanol-water mixture and dried under vacuum. 
Yield: 0.132 g (50.2%). IR (KBr, cm−1) 3,394 s υ (N-H), 2,833 s υ (C-H), 1,595 s υ (C=N), 1,243 s υ 
(C-C), 1,137 s υ (C-N). 1H-NMR (DMSO-d6), δ, ppm: 2.01 (s, 3H, CH3-iminic), 2.32 (s, 1H, NH) 2.64 
(d, 4H, 2CH2N), 3.55 (t, 4H, 2CH2NH) 6.15 (t, arH, CHCOHCHCOH), 7.31 (s, 1H, arH, 
OHCCHCOH), 7.33 (d, arH, CHCHCOHCHCOH), 7.53 (s, 1H, arH, OHCCHCOH), 7.55 (s, 1H, 
phenolic) 13C-NMR (DMSO-d6), δ, ppm: 18.96 (CH3), 26.27 (CH2), 39.46–40.09 (DMSO-d6 + CH2), 
54.34–58.54 (CH2), arC: [104.62 (CH), 111.20 (CH), 131.02 (CH), 133.75 (CH), 163.09 (CH), 172.28 
(CH)]; UV: 246 nm (8155.26 mol−1Lcm−1), 283 nm (29869.29 mol−1Lcm−1). MS: calc. m/z 263.34, 
found 264.17 (M+H). 
3.5. Anti-AChE Assay 
The anti-cholinesterase activities of the compounds were evaluated by Ellmann’s method with 
slight modifications, using acetylthiocholine as a substrate [29] and 5,5’-dithiobis[2-nitrobenzoic 
acid](DTNB). Sodium phosphate buffer (pH 8.0, 110 μL) was added into the 96 wells followed by 
sample solution (20 μL), DTNB (0.126 mM, 50 μL) and AChE enzyme (0.6 U/mL, 20 μL). The 
mixture was incubated for 50 minutes at 37 °C. The reaction was then initiated by the addition of 
acetylthiocholine iodide (0.120 mM, 50 μL). The hydrolysis of acetylthiocholine was monitored by  
the formation of yellow 5-thio-2-nitrobenzoate anion as the result of the reaction of DTNB with 
thiocholine, released by the enzymatic hydrolysis of acetylthiocholine, at a wavelength of 412 nm 
every 30 s for 25 min using a 96-well microplate plate reader (TECAN Infinite M200, Mannedorf, 
Switzerland). Test compounds were dissolved in analytical grade DMSO. Tacrine and propidium 
iodide were used as reference standards [30]. The reactions were performed in triplicate and monitored 
with a spectrophotometer. The percent inhibition of the enzyme activity due to the presence of 
increasing test compound concentration was obtained from the expression; 100 − (vi/vo × 100), where 
vi is the initial rate calculated in the presence of inhibitors and vo is the enzyme activity. 
3.6. Molecular Modeling Evaluations 
The pdb structure of human acetylcholinesterase (hAChE) (pdb ID: 1B41) was obtained from the 
Protein Data Bank. Hydrogen atoms were added to the structure, and all ionizable residues were set at 
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their default protonation state at a neutral pH. The 3D structure of the ligand was constructed using 
ChemBio Office 2008 and optimized according to the standard protocol in Accelrys Discovery Studio 
2.1. Docking studies were then carried using CDOCKER protocol at the active site of hAChE based  
on the Binding-Site module. CDOCKER is a grid based molecular docking method that employs 
CHARMm. The receptor is held rigid while the ligands are allowed to flex during the refinement. 
Random ligand conformations are generated from the initial ligand structure through high temperature 
molecular dynamics, followed by random rotations followed by refinement by grid-based (GRID 1) 
simulated annealing and a final grid-based or full force field minimization. In this experiment, the 
ligand was heated to a temperature of 700 K in 2,000 steps. The cooling steps were set to 5,000 steps 
with 300 K cooling temperature. The grid extension was set to 8 Å and ten conformations were set for 
the ligand. The pose with the highest –CDOCKER energy was taken for further analysis [31]. 
3.7. Antioxidant Activity 
3.7.1. FRAP Assay 
The FRAP assay of the compounds performed using modified method as described by Benzie and 
Strain [32]. The stock solutions contained 300 mM acetate buffer (3.1 g C2H3NaO2·3H2O and  
16 mL C2H4O2), pH 3.6, 10 mM TPTZ (2,4,6-tripyridyl-s-triazine) solution in 40 mM hydrochloric 
acid and 20 mM ferric chloride hexahydrate solution. The fresh working solution was prepared by 
mixing acetate buffer (25 mL), TPTZ (2.5 mL), and ferric chloride hexahydrate solution (2.5 mL). The 
temperature of the solution was raised to 37 °C before use and allowed to react with the FRAP solution 
(300 μL) in the dark. The colored product (ferrous tripyridyltriazine complex) was monitored at a 
wavelength of 593 nm. The standard curve was linear between 100 and 1,000 μM ferrous sulphate. 
Results are expressed in μM ferrous/g dry mass and compared with that of ascorbic acid and butylated 
hydroxytoluene. 
3.7.2. DPPH (1,1-Diphenyl-2-picrylhydrazyl) Assay 
The scavenging activities of the compounds on DPPH were recorded according to a reported 
procedure [33]. The compounds showed final concentrations within the range of 0–25 µg/mL in 
methanol. One milliliter of 0.3 mM DPPH ethanol solution was added to sample solution (2.5 mL) of 
different concentrations and used as stock solutions for the test; meanwhile methanol (1 mL) was 
added to samples (2.5 mL) to make the blank solutions. The negative control (blank) consisted of 
DPPH solution (1 mL) plus methanol (2.5 mL). These solutions were allowed to react at room 
temperature for 30 min in the dark. The absorbance was read at 518 nm and converted into percentage 
antioxidant activity according to the following equation: % Inhibition = [(AB − AA)/AB] × 100. Where: 
AB: absorption of blank sample, AA: absorption of tested samples. The kinetics of DPPH scavenging 
activity was determined and the IC50 calculated using ascorbic acid as a positive control. 
3.8. Acute Toxicity 
The acute toxicity study was carried out using seventy healthy Sprague Dawley rats of either sex 
weighing between 120–150 g. All animals were obtained from the Experimental Animal House, 
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Faculty of Medicine, University of Malaya, and were divided into seven groups of ten rats each (five 
males and five females for each group) labeled as control/vehicle (distilled); high dose (5 g/kg) and 
low dose (2 g/kg) of each of the compounds LP, 2HP and DHP in vehicle. Animals were fasted 
overnight (food but not water) prior to dosing. Food was withheld for a further 3 to 4 h after dosing. 
The animals were observed for general behavioral changes and mortality every four hours  
for the period of two weeks and sacrificed on the 15th day. Serum biochemical parameters were 
determined following standard methods [34]. The experimental animals received human care 
according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by 
the National Academy of Sciences and published by the National Institutes of Health [35]. The 
biochemical analysis was performed at the University Malaya Medical Center laboratory. The blood 
was centrifuged at 4,000 rpm for 10 min, serum separated and stored at −20 °C until determination of 
aspartate amino transferase (AST), alanine amino transferase (ALT), total cholesterol (TC), low density 
lipoprotein (LDL), high density lipoprotein (HDL), triglyceride (TG), alkaline phosphatase (ALP), total 
bilirubin (TB), conjugated bilirubin (CB), total protein (TP), globulins and albumin (ALB). Renal 
function indices, such as the concentration of creatinine, urea, sodium, chloride, potassium and 
inorganic phosphorus were also analyzed. Ethical approval was obtained from the Experimental 
Scientific Committee, Faculty of Medicine, University of Malaya. 
3.9. Statistical Analysis 
Statistical analysis was carried out using SPSS software version 19.0 and the results expressed as 
mean ± S.E.M. of the calculated value in each experiment using a one-way analysis of variance, 
followed by least significance difference (LSD) test for multiple comparisons 
4. Conclusions 
The novel Schiff bases potentially useful for cholinesterase inhibition were synthesized and 
characterized. The compounds were found to be safe in animal tests and showed good to moderate 
AChE inhibition activities. The hydrophobic interaction between the Schiff base DHP and the rich 
aromatic contents of the enzyme along the gorge directed the phenyl ring to penetrate deeply into the 
anionic site and oxyanion hole regions in the choline-binding site. This interaction is further 
intensified, whereby three hydrogen bonding were found between the Schiff base DHP and the 
residues in the active site, as confirmed by molecular docking. The antioxidant study indicated fairly 
good activities in the FRAP assay for all the compounds, while in the DPPH assay only the compound 
DHP showed activity. 
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